Dual-targeting immunotherapy of lymphoma: Potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

Blood

Volumn 119, Issue 16, 2012, Pages 3767-3778

  Gupta, Pankaj ^a   Goldenberg, David M ^b   Rossi, Edmund A ^c   Cardillo, Thomas M ^a   Byrd, John C ^d   Muthusamy, Natarajan ^d   Furman, Richard R ^e   Chang, Chien Hsing ^a,c  

^a IMMUNOMEDICS INC   (United States)

^b CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^c IBC Pharmaceuticals   (United States)

^d BAYLOR UNIVERSITY   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CATHEPSIN B; CD20 ANTIBODY; CD74 ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; MILATUZUMAB; MONOCLONAL ANTIBODY; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE; VELTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; ENZYME RELEASE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; LYSOSOME MEMBRANE; MANTLE CELL LYMPHOMA; MEMBRANE PERMEABILITY; MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

EID: 84860332847     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-381988     Document Type: Article

References (50)

1. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(22):5044-5051. (Pubitemid 46224011)
2. Strauss SJ, Morschhauser F, Rech J, et al. Multi-center phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2006;24(24):3880-3886. (Pubitemid 46630735)
3. Leonard JP, Schuster SJ, Emmanouilides C, et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer. 2008;113(10):2714-2723.
4. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23(9):1984-1992. (Pubitemid 46211378)
5. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23(28):7013-7023.
6. Inwards DJ, Fishkin PA, Hillman DW, et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer. 2008;113(1):108-116. (Pubitemid 351980749)
7. Lossos IS, Hosein PJ, Morgensztern D, et al. High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma. Leuk Lymphoma. 2010;51(3):406-414.
8. Sachanas S, Pangalis GA, Vassilakopoulos TP, et al. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leuk Lymphoma. 2011;52(3):387-393.
9. Baiocchi RA, Alinari L, Lustberg ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011;117:2442-2451.
10. Diefenbach CS, O'Connor OA. Mantle cell lymphoma in relapse: the role of emerging new drugs. Curr Opin Oncol. 2010;22(5):419-423.
11. Leng L, Metz CN, Fang Y, et al. MIF signal transduction initiated by binding to CD74. J Exp Med. 2003;197(11):1467-1476. (Pubitemid 36686708)
12. Landsverk OJ, Bakke O, Gregers TF. MHC II and the endocytic pathway: regulation by invariant chain. Scand J Immunol. 2009;70(3):184-193.
13. Young AN, Amin MB, Moreno CS, et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol. 2001; 158(5):1639-1651. (Pubitemid 32422929)
14. Koide N, Yamada T, Shibata R, et al. Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer. Clin Cancer Res. 2006;12(8):2419-2426.
15. Meyer-Siegler KL, Iczkowski KA, Vera PL. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer. 2005;5:73.
16. Stein R, Mattes MJ, Cardillo TM, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007;13(18 pt 2):5556s-5563s. (Pubitemid 47510387)
17. Alinari L, Yu B, Christian BA, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011;117(17):4530-4541.
18. Rossi EA, Goldenberg DM, Cardillo TM, et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A. 2006;103(18):6841-6846.
19. Chang CH, Rossi EA, Goldenberg DM. The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res. 2007;13(18 pt 2):5586s-5591s. (Pubitemid 47510391)
20. Rossi EA, Goldenberg DM, Cardillo TM, et al. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res. 2008;68(20):8384-8392.
21. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics, 1: Properties of anti-CD20/CD22 antibodies in lymphoma. Blood. 2009;113(24):6161- 6171.
22. Gupta P, Goldenberg DM, Rossi EA, Chang CH. Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. Blood. 2010;116(17): 3258-3267.
23. Jeon HJ, Kim CW, Yoshino T, Akagi T. Establishment and characterization of a mantle cell lymphoma cell line. Br J Haematol. 1998;102(5): 1323-1326. (Pubitemid 28435219)
24. Jadayel DM, Lukas J, Nacheva E, et al. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia. 1997; 11(1):64-72. (Pubitemid 27065051)
25. Lai R, McDonnell TJ, O'Connor SL, et al. Establishment and characterization of a new mantle cell lymphoma cell line, Mino. Leuk Res. 2002; 26(9):849-855. (Pubitemid 34778500)
26. Mayo MW, Norris JL, Baldwin AS. Ras regulation of NF-kappa B and apoptosis. Methods Enzymol. 2001;33373-33387.
27. Drose S, Altendorf K. Bafilomycins and concanamycins as inhibitors of V-ATPases and P-ATPases. J Exp Biol. 1997;200(Pt 1):1-8. (Pubitemid 27058890)
28. Stein R, Gupta P, Chen X, et al. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. Blood. 2010;115(25):5180-5190.
29. Vega MI, Huerta-Yepaz S, Garban H, et al. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene. 2004; 23(20):3530-3540. (Pubitemid 38658419)
30. Droken B, Moller P, Pezzutto A, Schwartz-Albiex R, Moldenhauer G. B-cell antigen: CD74. In: Knapp W, ed. Leukocyte Typing IV: White Cell Differentiation Antigens. Oxford, United Kingdom: Oxford University Press; 1989:106.
31. Weenink SM, Gautam AM. Antigen presentation by MHC class II molecules. Immunol Cell Biol. 1997;75(1):69-81. (Pubitemid 27101410)
32. Shi X, Leng L, Wang T, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity. 2006;25(4):595-606. (Pubitemid 44529040)
33. Becker-Herman S, Arie G, Medvedovsky H, Kerem A, Shachar I. CD74 is a member of the regulated intramembrane proteolysis-processed protein family. Mol Biol Cell. 2005;16(11):5061-5069. (Pubitemid 41566819)
34. Starlets D, Gore Y, Binsky I, et al. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood. 2006;107(12): 4807-4816. (Pubitemid 43882632)
35. Binsky I, Haran M, Starlets D, et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci U S A. 2007;104(33):13408- 13413. (Pubitemid 47293958)
36. Shachar I, Haran M. The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival. Leuk Lymphoma. 2011;52(8):1446-1454.
37. Borghese F, Clanchy FI. CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease. Expert Opin Ther Targets. 2011;15(3):237-251.
38. Lim SH, Beers SA, French RR, et al. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica. 2010;95(1):135-143.
39. Pawluczkowycz AW, Beurskens FJ, Beum PV, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFAthan by RTX. J Immunol. 2009;183(1):749-758.
40. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22): 4393-4402.
41. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44(16):3823-3837. (Pubitemid 47332625)
42. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003; 101(3):1045-1052. (Pubitemid 36139378)
43. Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother. 2002;51(1):15-24. (Pubitemid 34158519)
44. Beers SA, Chan CH, James S, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood. 2008;112(10):4170-4177.
45. Zhuang S, Schnellmann RG. A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther. 2006;319(3):991-997.
46. Ivanov A, Krysov S, Cragg MS, Illidge T. Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin Cancer Res. 2008;14(15): 4925-4934.
47. di Mari JF, Davis R, Safirstein RL. MAPK activation determines renal epithelial cell survival during oxidative injury. Am J Physiol. 1999;277(2 pt 2):F195-F203. (Pubitemid 29415137)
48. Kansas GS, Tedder TF Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J Immunol. 1991;147(12):4094-4102.
49. Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009;119(8):2143- 2159.
50. Xie L, Qiao X, Wu Y, Tang J. β-Arrestin1 mediates the endocytosis and functions of macrophage migration inhibitory factor. PLoS One. 2011;6(1): e16428.